References
- Abu-El-Haija, B., Giudici, M. C. (2014). Predictors of long-term maintenance of normal sinus rhythm after successful electrical cardioversion. Clin. Cardiol.,37 (6), 381–385.
- Barekatain, A., Razavi, M. (2012). Antiarrhythmic therapy in atrial fibrillation. Indications, guidelines, and safety. Tex. Heart Inst. J.,39 (4), 532–534.
- Chugh, S. S., Havmoeller, R., Narayanan, K., Singh, D., Rienstra, M., Benjamin, E. J., Gillum, R. F., Kim, Y. H., McAnulty Jr., J. H., Zheng, Z. J., Forouzanfar, M. H., Naghavi, M., Mensah, G. A., Ezzati, M., Murray, C. J. L. (2014). Worldwide epidemiology of atrial fibrillation: A global burden of disease 2010 study. Circulation,129 (8), 837–847.
- Dan, G. A., Martinez-Rubio, A., Agewall, S., Boriani, G., Borggrefe, M., Gaita, F., van Gelder, I., Gorenek, B., Kaski, J. C., Kjeldsen, K., et al. (2018). Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP). Europace,20 (5), 731–732.
- Dorian, P., Angaran, P. (2014). β-blockers and atrial fibrillation: Hypertension and other medical conditions influencing their use. Can. J. Cardiol.,30 (5 Suppl), S38–41.
- Ecker, V., Knoery, C., Rushworth, G., Rudd, I., Ortner, A., Begley, D., Leslie, S. J. (2018). A review of factors associated with maintenance of sinus rhythm after elective electrical cardioversion for atrial fibrillation. Clin. Cardiol.,41 (6), 862–870.
- Elnaggar, M. N., Jbeili, K., Nik-Hussin, N., Kozhippally, M., Pappachan, J. M. (2018). Amiodarone-induced thyroid dysfunction: A clinical update. Exp. Clin. Endocrinol. Diabetes,126 (6), 333–341.
- Faber, T. S., Camm, A. J. (1996). The differentiation of propafenone from other class IC agents, focusing on the effect on ventricular response rate attributable to its beta-blocking action. Eur. J. Clin. Pharmacol.,51 (3–4), 199–208.
- Falsetti, L., Viticchi, G., Tarquinio, N., Silvestrini, M., Capeci, W., Balloni, A., Catozzo, V., Gentile, A., Pellegrini, F. (2014). CHA2DS2-VASc in the prediction of early atrial fibrillation relapses after electrical or pharmacological cardioversion. J. Cardiovasc. Med. (Hagerstown),15 (8), 636–641.
- Galperin, J., Elizari, M. V., Bonato, R., Ledesma, R., Vazquez Blanco, M., Lago, M., Spada, P., Sanchez, J., Piasentin, J., Chiale, P. A. (2014). Short-term amiodarone therapy after reversion of persistent atrial fibrillation reduces recurrences at 18 months. Cardiol. J.,21 (4), 397–404.
- Gonna, H., Gallagher, M. M. (2014). The efficacy and tolerability of commonly used agents to prevent recurrence of atrial fibrillation after successful cardioversion. Amer. J. Cardiovasc. Drugs,14 (4), 241–251.
- Grandi, E., Ripplinger, C. M. (2019). Antiarrhythmic mechanisms of beta blocker therapy Pharmacol. Res.,146, 104274.
- Gwag, H. B., Chun, K. J., Hwang, J. K., Park, S. J., Kim, J. S., Park, K. M., On, Y. K. (2018). Which antiarrhythmic drug to choose after electrical cardioversion: A study on non-valvular atrial fibrillation patients. PLoS One,13 (5), e0197352.
- Kirchhof, P., Andresen, D., Bosch, R., Borggrefe, M., Meinertz, T., Parade, U., Ravens, U., Samol, A., Steinbeck, G., Treszl, A., Wegscheider, K., Breithardt, G. (2012). Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): A prospective, randomised, open-label, blinded endpoint assessment trial. Lancet,380 (9838), 238–246.
- Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H. C., Heidbuchel, H., Hendriks, J., et al. (2016). 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur. Heart J.,37 (38), 2893–2962.
- Klein, H. H., Trappe, H. J. (2015). Cardioversion in non-valvular atrial fibrillation. Dtsch. Arztebl. Int.,112 (50), 856–862.
- Lafuente-Lafuente, C., Valembois, L., Bergmann, J. F., Belmin, J. (2015). Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst. Rev.,3, CD005049.
- Lip, G. Y., Fauchier, L., Freedman, S. B., Van Gelder, I., Natale, A., Gianni, C., Nattel, S., Potpara, T., Rienstra, M., Tse, H. F., Lane, D. A. (2016). Atrial fibrillation. Nat. Rev. Dis. Primers,2, 16016.
- Lip, G. Y. H., Kamath, S. (2000). Atrial fibrillation (2) Antiarrhythmic agents. The Pharm. J.,264 (7094), 659–663.
- Martínez-Brotóns, A. M., Ruiz-Granell, R., Morell, S., Plancha, E., Ferrero, A., Roselló, A., Llácer, A., García-Civera, R. (2006). Therapeutic Success of a prospective cardioversion protocol for persistent atrial fibrillation. Rev. Esp. Cardiol.,59 (10), 1038–1046.
- Papiris, S. A., Triantafillidou, C., Kolilekas, L., Markoulaki, D., Manali, E. D. (2010). Amiodarone: Review of pulmonary effects and toxicity. Drug Saf.,33 (7), 539–558.
- Park, H. S., Kim, Y. N. (2014). Adverse effects of long-term amiodarone therapy. Korean J. Intern. Med.,29 (5), 571–573.
- Piccini, J. P., Fauchier, L. (2016). Rhythm control in atrial fibrillation. Lancet,388 (10046), 829–840.
- Pokorney, S. D., Kim, S., Thomas, L., Fonarow, G. C., Kowey, P. R., Gersh, B. J., Mahaffey, K. W., Peterson, E. D., Piccini, J. P. (2017). Cardioversion and subsequent quality of life and natural history of atrial fibrillation. Amer. Heart J.,185, 59–66.
- Qin, D., Leef, G., Alam, M.B., Rattan, R., Munir, M. B., Patel, D., Khattak, F., Vaghasia, N., Adelstein, E., Jain, S. K., Saba, S. (2015). Patient outcomes according to adherence to treatment guidelines for rhythm control of atrial fibrillation. J. Amer. Heart Assoc.,4 (4), e001793.
- Rajagopalan, B., Curtis, A. B. (2012). Contemporary approach to electrical and pharmacological cardioversion of atrial fibrillation. Postgrad. Med.,124 (6), 26–35.
- Roden, D. M. (2000). Antiarrhythmic drugs: from mechanisms to clinical practice. Heart,84 (3), 339–346.
- Saliba, W., Wazni, O. M. (2011). Sinus rhythm restoration and treatment success: Insight from recent clinical trials. Clin. Cardiol.,34 (1), 12–22.
- Sardar, M. R., Saeed, W., Kowey, P. R. (2016). Antiarrhythmic drug therapy for atrial fibrillation. Heart Fail. Clin.,12 (2), 205–221.
- Schilling, R. J. (2010). Cardioversion of atrial fibrillation: The use of antiarrhythmic drugs. Heart,96 (5), 333–338.
- Singla, S., Karam, P., Deshmukh, A. J., Mehta, J., Paydak, H. (2012). Review of contemporary antiarrhythmic drug therapy for maintenance of sinus rhythm in atrial fibrillation. J. Cardiovasc. Pharmacol. Ther.,17 (1), 12–20.
- Stoschitzky, K., Stoschitzky, G., Lercher, P., Brussee, H. (2017). Oral loading of propafenone: Restoring its role before restoring rhythm-authors’ reply. Europace,19 (11), 1903–1904.
- Stoschitzky, K., Stoschitzky, G., Lercher, P., Brussee, H., Lamprecht, G., Lindner, W., 2016. Propafenone shows class Ic and class II antiarrhythmic effects. Europace,18 (4), 568–571.
- Vitali, F., Serenelli, M., Airaksinen, J., Pavasini, R., Tomaszuk-Kazberuk, A., Mlodawska, E., Jaakkola, S., Balla, C., Falsetti, L., Tarquinio, N., Ferrari, R., Squeri, A., Campo, G., Bertini, M. (2019). CHA2DS2-VASc score predicts atrial fibrillation recurrence after cardioversion: Systematic review and individual patient pooled meta-analysis. Clin. Cardiol.,42 (3), 358–364.
- Waks, J. W., Zimetbaum, P. (2017). Drug therapy for rhythm control in atrial fibrillation J. Cardiovasc. Pharmacol. Ther.,22 (1), 3–19.
- Zimetbaum, P. (2017). In the clinic: Atrial fibrillation. Ann. Intern. Med.,166 (5), ITC33–ITC48.